SCHEMBL29907209

SCHEMBL29907209

COc1cc2c(nc1-c1cccc3c1CCC3)c(-c1ccc(CO)nc1)nn2C(=O)OC(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 1/20 0.36
UCHL1 P09936 2/20 0.33
STAT3 P40763 1/20 0.33
PGK1 P00558 1/20 0.32
ALOX5 P09917 2/20 0.31
MAP2K4 P45985 1/20 0.31
JAK2 O60674 3/20 0.31
JAK1 P23458 3/20 0.31
TYK2 P29597 3/20 0.31
JAK3 P52333 3/20 0.31
KCNH2 Q12809 1/20 0.31
ATM Q13315 1/20 0.31
ATR Q13535 1/20 0.31
CFTR P13569 1/20 0.31
ALK Q9UM73 1/20 0.31
EHMT2 Q96KQ7 1/20 0.30
PTGIR P43119 1/20 0.30
PTGDR Q13258 1/20 0.30
GSK3B P49841 1/20 0.30
DYRK1A Q13627 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23211054 1.00 TNF (0.36) TNFUCHL1STAT3PGK1ALOX5
SCHEMBL23211050 0.91 SCN9A (0.32) UCHL1STAT3PGK1ALOX5ALK
SCHEMBL29907073 0.91 SCN9A (0.32) UCHL1STAT3PGK1ALOX5ALK
SCHEMBL23211084 0.90 GYS1 (0.33) JAK2JAK1TYK2JAK3KCNH2
SCHEMBL29907072 0.89 STAT3 (0.33) UCHL1STAT3PGK1MAP2K4CFTR
SCHEMBL30308837 0.89 STAT3 (0.33) UCHL1STAT3PGK1MAP2K4CFTR
SCHEMBL23211071 0.89 STAT3 (0.33) UCHL1STAT3PGK1MAP2K4CFTR
SCHEMBL23210982 0.82 MEN1 (0.35) UCHL1STAT3MAP2K4JAK2JAK3
SCHEMBL29907071 0.82 MEN1 (0.35) UCHL1STAT3MAP2K4JAK2JAK3
SCHEMBL23210935 0.81 SCN9A (0.33) ALOX5PTGIRPTGDRGYS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250057852-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2025-02-20 US disclosed
CN-115835908-A Bicyclic heterocycles as FGFR inhibitors 因赛特公司 2023-03-21 CN disclosed
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2023-03-21 US disclosed
EP-4045151-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS Incyte Corporation (US) 2022-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250057852-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 TNF 4766/4885UCHL1 3551/4885STAT3 1131/4885
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors FGFR1, FGFR3, FGFR2 TNF 4766/4885UCHL1 3551/4885STAT3 1131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.